Skip to main content

Market Overview

Dyadic's COVID-19 Vaccine Candidate Comes One Step Closer To Enter Human Trials


Dyadic International Inc's (NASDAQ: DYAI) initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, moves towards the first human Phase 1 clinical trial to assess the safety and preliminary efficacy of the vaccine.

  • The company has entered into a master services agreement with CR2O, a contract research organization, to manage the preclinical and clinical development of DYAI-100.
  • The toxicology study expected to begin in Q2, and the first-in-human Phase 1 trial will start in the second half of this year.
  • Preclinical results indicate safety, efficacy, and protection in animal studies conducted by the Israel Institute for Biological Research, including the recently reported successful challenge studies using human ACE2 transgenic mice vaccinated with DYAI-100.
  • Price Action: DYAI shares are trading 5.6% higher at $5.05 in premarket on the last check Thursday.

Related Articles (DYAI)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Penny Stocks Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at